Tag Archives: SGLT2 inhibitors

Managing type 2 diabetes today can feel like solving a moving puzzle. With so many therapies available, how do clinicians decide what comes next? GLP-1 therapies have become a key part of today’s diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences. As treatment options evolve, …

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

When managing type 2 diabetes, should clinicians still begin with one medication and wait for treatment failure before intensifying therapy? Increasingly, evidence suggests that early combination therapy in type 2 diabetes may provide better durability, faster glycemic control, and improved cardiovascular and kidney outcomes in high-risk patients. While metformin monotherapy …

As GLP-1 receptor agonists dominate headlines and prescribing trends, many clinicians wonder whether older therapies are losing relevance. However, SGLT2 inhibitors remain foundational in type 2 diabetes care. More importantly, evidence now supports the use of SGLT2 inhibitors and GLP-1 combination therapy in patients at high cardiovascular and renal risk. …

What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

Diabetic ketoacidosis (DKA) continues to be one of the most dangerous acute complications faced by people with diabetes, particularly those on insulin or SGLT2 inhibitors. While traditional approaches rely on intermittent blood ketone checks, a new frontier is emerging—continuous ketone monitoring for DKA prevention. This article explores how this technology …

  As the burden of diabetic kidney disease (DKD) continues to grow, so does the urgency for early, evidence-based interventions. The concept of kidney protection diabetes is shifting—clinicians are now encouraged to initiate therapy before substantial kidney function loss occurs. Two major drug classes—SGLT2 inhibitors and GLP‑1 receptor agonists—are leading …

Treating type 2 diabetes is no longer a one-size-fits-all endeavor. As new therapies emerge, clinicians face the ongoing challenge of selecting and sequencing medications in a way that balances efficacy, safety, cost, and patient preference. This comprehensive guide to type 2 diabetes drug sequencing outlines practical strategies for initiating, intensifying, …